|
|
Post by veritasfiliatemporis on Jun 24, 2019 16:23:32 GMT -5
Meanwhile we are discussing about VDEX we can also read the new RLS article. I presume...đ¤
|
|
|
|
Post by rtmd on Jun 24, 2019 16:25:38 GMT -5
|
|
|
|
Post by mnkdfann on Jun 24, 2019 16:31:41 GMT -5
I'm not quite sure what is old or new content on that site (so this next may be old), but there is a Mannkind mention here under Wesner's entry: www.receptorlife.com/leadership |
|
|
|
Post by veritasfiliatemporis on Jun 24, 2019 17:00:15 GMT -5
Press release is brand new, they are going to hit a huge sector in a close connection with Mannkind, can we say it's a good news and leave the VDEX annoying stuff... Just saying..
|
|
|
|
Post by rtmd on Jun 24, 2019 17:11:00 GMT -5
The news would be better if they included a page describing their pipeline. Anymore, everyone and their brother is developing some cannabis related product.
|
|
|
|
Post by wyattdog on Jun 24, 2019 17:22:22 GMT -5
i like this. Receptorâs dry powder inhalation technology, Receptor AIRâ˘, exclusively licensed from MannKind Corporation, resulted from Mr. Wesnerâs experience as intellectual property counsel to MannKind. Mr. Wesner managed an exhaustive analysis of worldwide pulmonary drug delivery technologies and became convinced MannKindâs inhalation system is the only one capable of safely, reliably and precisely delivering cannabinoid-based drugs rapidly to the bloodstream. That insight led to Receptor and MannKindâs global partnership.
|
|
|
|
Post by peppy on Jun 24, 2019 17:43:25 GMT -5
The news would be better if they included a page describing their pipeline. Anymore, everyone and their brother is developing some cannabis related product. RLS is going to try to get FDA approval for their cannabis product. Nausea and all. |
|
|
|
Post by mango on Jun 24, 2019 19:45:47 GMT -5
I'll be honestâI've been smoking almost exclusively CBD flowers the past few months, and very little THC dominate chemovars. It has significantly helped me with addiction, depression, and anxiety. I'm really really looking forward to what RLS has in store for the future, and I'm really excited to see that they are slowing laying their foundation for groundbreaking products in this space. It's due time for good vibes đ The RLS SAB includes international experts in epilepsy, pain management, migraine, anxiety, post-traumatic stress disorder (PTSD), autism spectrum disorder, child psychiatry, sleep disorders, clinical pharmacology and clinical trials.
"The Receptor Life Sciences Scientific Advisory Board includes some of the leading clinicians and researchers in the United States," said Orrin Devinsky, MD, Chief Medical Officer, RLS and Professor of Neurology, Neurosurgery, & Psychiatry at NYU Langone Health.
The SAB includes faculty from leading medical institutions including, Albert Einstein College of Medicine, New York University, University of Minnesota, and University of Indiana, and others. Collectively, the SAB has contributed to more than 2,300 articles in the medical literature.
The SAB will help leverage RLS' pipeline of cannabinoid products for specific indications. The SAB will also guide partnerships with medical research institutions to advance RLS's product portfolio.James Cloyd III, Pharm Dwww.pharmacy.umn.edu/bio/experimental-and-clinical-phar/james-cloydDaniel Friedman MD, MScnyulangone.org/doctors/1407900152/daniel-friedmanBrian Hainline, MDwww.ncaa.org/sport-science-institute/about-ssiRichard B. Lipton, MDwww.einstein.yu.edu/faculty/7405/richard-liptonCharles R. Marmar, MDneurosciencecme.com/cmea_popup_faculty.asp?ID=488 |
|
|
|
Post by sayhey24 on Jun 24, 2019 20:15:49 GMT -5
The news would be better if they included a page describing their pipeline. Anymore, everyone and their brother is developing some cannabis related product. IMO, the first four areas listed in the PR is their near term pipeline; epilepsy; pain management; migraine; anxiety. If they can pull off just "pain" with the opioid mess going on they have hit a home run. Mike mentioned at JPM they have 2 molecules ready to go. Maybe we will get more news soon. |
|
|
|
Post by barnstormer on Jun 25, 2019 7:52:07 GMT -5
So the question I ask to those of you with experiance, as RLS states that they are developing drugs for FDA approval. What would be a realistic time frame for any of them to be marketable, 3-5 years and which ones could be considered "over the counter"?
|
|
|
|
Post by ktim on Jun 25, 2019 10:48:44 GMT -5
So the question I ask to those of you with experiance, as RLS states that they are developing drugs for FDA approval. What would be a realistic time frame for any of them to be marketable, 3-5 years and which ones could be considered "over the counter"?If it's from marijuana it is still illegal in the eyes of the feds. If it's CBD from hemp with less than 0.3% THC then it is legal under federal but illegal in some states and controlled by federal regulations if sold with therapeutic claims. www.nytimes.com/2019/05/06/us/cbd-cannabis-marijuana-hemp.htmlThere are not yet any oral CBD products sold in national pharmacy chains, to my knowledge. |
|
|
|
Post by nylefty on Jun 25, 2019 11:35:13 GMT -5
|
|
|
|
Post by ktim on Jun 25, 2019 11:48:19 GMT -5
Thanks, that does confirm that as of end of April those three chains were offering only topical CBD products not oral/ingestible CBD products. That is what I seemed to remember. |
|
|
|
Post by peppy on Jun 25, 2019 17:08:53 GMT -5
So the question I ask to those of you with experiance, as RLS states that they are developing drugs for FDA approval. What would be a realistic time frame for any of them to be marketable, 3-5 years and which ones could be considered "over the counter"? my understanding is some epilepsy RLS/CBD/THC may fall under the fast track. The Orphan Drug Act (ODA) provides for granting special status to a drug or biological product (âdrugâ) to treat a rare disease or condition upon request of a sponsor. ... A sponsor seeking orphan designation for a drug must submit a request for designation to OOPD with the information required in 21 CFR 316.20 and 316.21. Pictured below is our visible stupidity and corruption. The insert, the child is on pharmaceutical drugs to control seizures, pictured below the same child with out seizures on CBD/cannabis. How can we accept this stupidity/corruption of big Pharma/FDA/congress/ on our children? Ad Nauseam  |
|
|
|
Post by mango on Jun 25, 2019 17:42:56 GMT -5
So the question I ask to those of you with experiance, as RLS states that they are developing drugs for FDA approval. What would be a realistic time frame for any of them to be marketable, 3-5 years and which ones could be considered "over the counter"? my understanding is some epilepsy RLS/CBD/THC may fall under the fast track. The Orphan Drug Act (ODA) provides for granting special status to a drug or biological product (âdrugâ) to treat a rare disease or condition upon request of a sponsor. ... A sponsor seeking orphan designation for a drug must submit a request for designation to OOPD with the information required in 21 CFR 316.20 and 316.21. Pictured below is our visible stupidity and corruption. The insert, the child is on pharmaceutical drugs to control seizures, pictured below the same child with out seizures on CBD/cannabis. How can we accept this stupidity/corruption of big Pharma/FDA/congress/ on our children? Ad Nauseam RLS Scientific Advisor Board: James Cloyd III, Pharm D, Morse Alumni Distinguished Teaching Professor of Pharmacy and Neurology, the Lawrence C. Weaver Endowed Chair in Orphan Drug Development, and Director of the Center for Orphan Drug Research at the University of Minnesota College of Pharmacy. Daniel Friedman MD, MSc, Associate Professor of Neurology at NYU Langone Health. His expertise includes epilepsy, clinical trial methodology, novel trial designs, and outcomes research. |
|
